Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | KDR | P35968 | 6/20 | 0.41 |
| ▸ | TEK | Q02763 | 4/20 | 0.41 |
| ▸ | CNR2 | P34972 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18328986 | 0.89 | TP53 (0.55) | TP53KDRTEKCNR2ALDH1A1 | |
| SCHEMBL12608671 | 0.89 | TP53 (0.51) | TP53KDRTEKCNR2 | |
| SCHEMBL16120082 | 0.88 | TP53 (0.67) | TP53KDRTEKCNR2ALDH1A1 | |
| SCHEMBL12608691 | 0.86 | TP53 (0.49) | TP53KDRTEKCNR2NPC1 | |
| SCHEMBL15848979 | 0.84 | TP53 (0.52) | TP53KDRTEKCNR2ALDH1A1 | |
| SCHEMBL18328991 | 0.81 | SIGMAR1 (0.39) | TP53KDR | |
| SCHEMBL12608668 | 0.81 | TP53 (0.82) | TP53KDRTEK | |
| SCHEMBL12608669 | 0.81 | TP53 (0.82) | TP53KDRTEK | |
| SCHEMBL15848975 | 0.79 | TP53 (0.66) | TP53KDRTEKCNR2NPC1 | |
| SCHEMBL16454377 | 0.79 | TP53 (0.66) | TP53KDRTEKCNR2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160368872-A1 | COMPOUNDS AND METHODS FOR TREATING CANCERS | PANACELA LABS, INC. | 2016-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160368872-A1 | COMPOUNDS AND METHODS FOR TREATING CANCERS | KLK3, AR, BRDT | TP53 13/4885KDR 2457/4885TEK 456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.